Surgical Experience and Outcome Evaluation of Genital Gender Affirmation Surgery for Transgender Female in China: A Case Series
Aesthetic Plastic Surgery · 2025
DOI: 10.1007/s00266-024-04628-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aesthetic Plastic Surgery, 2025. Verfasst von Guanhuier Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic Surgery, Peking University 3rd Hospital, Beijing, 100191, China. Hauptthemen laut MEDLINE: Gender-Affirming Surgery, Transgender Persons. Die Arbeit nennt 21 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Social Science Fund of China.
Abstract (Originalsprache)
BACKGROUND: Gender-affirming surgery (GAS) for transgender females developed relatively late and limited in China due to some reasons. To introduce GAS surgical experiences for Chinese transgender females is necessary. AIMS: To report surgical choices and experience including clitoral/urethral reconstruction, vaginoplasty, and vulvoplasty, and their outcomes. METHODS: A single-center, retrospective case series was conducted among transgender females who underwent GAS between September 2018 and March 2023. Surgical outcomes were evaluated including short-term and long-term complications. Scar-Q Scale, Female Sexual Function Index (FSFI), Amsterdam Hyperactive Pelvic Floor Scale-Women (AHPFS-W), and Female Genital Self-Imaging Scale (FGSIS) were carried out for outcome evaluation. RESULTS: Thirteen transgender females underwent GAS. Among them, 7 patients underwent sigmoid colon vaginoplasty, 3 patients underwent zero-depth vaginoplasty (ZDV), and 3 patients underwent vaginoplasty using skin flap (penile or scrotum). Postoperative follow-up showed that for sigmoid colon neo-vagina, vaginal length can reach 10-15 cm, with a width of about 2 fingers. For skin flap neo-vagina, the long-term vaginal length can maintain at around 8-10 cm, with a width of about 2 fingers. AHPFS-W outcome shows that patients undergoing sigmoid colon vaginoplasty and ZDV have relatively better pelvic floor muscle function. Patients undergoing skin flap vaginoplasty scored higher on the FGSIS, indicating a higher level of self-acceptance toward reconstructed genitalia. DISCUSSION: Factors like anatomical characteristics, sexual customs and cultural backgrounds may alter the choice of GAS techniques for Chinese transgender females. The GAS surgical experience specialized to Chinese transgender females is necessary to share. LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Plastic Surgery, Peking University 3rd Hospital, Beijing, 100191, China.
- Department of Plastic Surgery, Peking University 3rd Hospital, Beijing, 100191, China. purlin_pan@sina.com.
ORCID-Profile: Bailin Pan
Förderung
- National Natural Science Foundation of China
- National Social Science Fund of China
Zitieren
APA
Wang, G., Chang, X., Yang, X., Zhao, R., Qian, J., Liu, Y., Xing, Q., & Pan, B. (2025). Surgical Experience and Outcome Evaluation of Genital Gender Affirmation Surgery for Transgender Female in China: A Case Series. Aesthetic Plastic Surgery. https://doi.org/10.1007/s00266-024-04628-4
Vancouver
Wang G, Chang X, Yang X, Zhao R, Qian J, Liu Y, et al. Surgical Experience and Outcome Evaluation of Genital Gender Affirmation Surgery for Transgender Female in China: A Case Series. Aesthetic Plastic Surgery. 2025. doi:10.1007/s00266-024-04628-4
BibTeX
@article{Wang2025,
author = {Wang, Guanhuier and Chang, Xu and Yang, Xin and Zhao, Runlei and Qian, Jiaying and Liu, Ye and Xing, Qiannan and Pan, Bailin},
title = {Surgical Experience and Outcome Evaluation of Genital Gender Affirmation Surgery for Transgender Female in China: A Case Series},
journal = {Aesthetic Plastic Surgery},
year = {2025},
doi = {10.1007/s00266-024-04628-4}
}
EUVIMED